[Application of lung cancer organoids in precision medicine]

Lung cancer is one of the leading causes of cancer-related death worldwide, and there is an urgent need to develop more reliable preclinical models to identify effective treatments. Moreover, lung cancer exhibits significant heterogeneity between individuals and requires precision medicine to achieve comprehensive management. Lung cancer organoids (LCOs) are derived from patients' tumor tissues or tumor cells, which enables them to faithfully recapitulate in vivo tumor characteristics and heterogeneity, providing a promising platform to study drug resistance mechanisms and predict therapy efficacy. Here, we described the construction of LCOs and their application in precision therapy. We also discussed the limitations and prospects of current organoids research.